Pinnacle Medicines raised $89 million in a Series B to advance its oral peptide programs, bringing total funding to $134 million. The round was co-led by LAV and Foresite Capital, strengthening the company’s ability to move multiple peptide candidates through development. The financing adds momentum to companies betting on oral delivery and peptide therapeutics, where formulation and stability challenges can determine whether pipelines translate into clinical differentiation. Pinnacle’s funding round also signals continued investor appetite for non-antibody modalities with clear dosing convenience. While no specific lead program details were provided in the announcement text, the size and structure of the Series B indicates capital prioritization for operational scale and clinical advancement.